GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received a consensus rating of "Hold" from the twelve ratings firms that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.80.

• Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial cut GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of GoodRx in a research note on Wednesday, October 8th.

View Our Latest Stock Analysis on GoodRx

GoodRx Trading Down 1.8%

• This healthcare stock making a buzz with 160% growth

Shares of GDRX stock opened at $3.83 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 38.30, a PEG ratio of 1.70 and a beta of 1.23. The stock has a 50-day moving average of $4.21 and a 200-day moving average of $4.37. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx has a 1-year low of $3.31 and a 1-year high of $6.97.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 EPS. On average, equities research analysts forecast that GoodRx will post 0.13 earnings per share for the current year.

Insiders Place Their Bets

• Gene therapy: Why does it cost millions for a single treatment?

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.53% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GDRX. CWA Asset Management Group LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $292,000. Teacher Retirement System of Texas purchased a new position in shares of GoodRx during the first quarter valued at approximately $218,000. Hohimer Wealth Management LLC boosted its position in shares of GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in shares of GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after buying an additional 2,748 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its position in shares of GoodRx by 20.3% during the first quarter. Allianz Asset Management GmbH now owns 278,077 shares of the company's stock valued at $1,226,000 after buying an additional 46,900 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Featured Articles

• Five stocks we like better than GoodRx
• What Are Dividend Challengers?
• This AI Chip Giant Could Be the Market’s Next Big Winner
• Stock Ratings and Recommendations: Understanding Analyst Ratings
• Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock
• CD Calculator: Certificate of Deposit Calculator
• Institutions Are Fueling CrowdStrike’s Next Leg Higher

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here